Adverts

Open Access Articles- Top Results for Alfuzosin

Alfuzosin

</th></tr></th></tr>
Alfuzosin
File:Alfuzosin.svg
File:Alfuzosin ball-and-stick.png
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade names Uroxatral
AHFS/Drugs.com monograph
MedlinePlus a64002
  • AU: B2
  • US: B (No risk in non-human studies)
Oral
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Half-life 10 hours
Excretion Fecal (69%) and renal (24%)
Identifiers
81403-80-7 7pxY
G04CA01
PubChem CID 2092
DrugBank DB00346 7pxY
ChemSpider 2008 7pxY
UNII 90347YTW5F 7pxY
KEGG D07124 7pxY
ChEBI CHEBI:51141 7pxY
ChEMBL CHEMBL709 7pxY
Chemical data
Formula C19H27N5O4
389.449 g/mol
 14pxY (what is this?)  (verify)

Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the alpha-1 blocker class. As an antagonist of the alpha-1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xat or Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.abdominal disturbances.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.